

Nxera Pharma

36th Ordinary General Meeting of Shareholders

25 March 2026 | Nxera Pharma Co., Ltd. (TSE: 4565)

Disclaimer

The material that follows is a presentation of general background information about Nxera Pharma Co., Ltd and its subsidiaries (collectively, the “Company”) as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities and should not be treated as giving investment advice to recipients. It is not targeted to the specific investment objectives, financial situation or particular needs of any recipient. It is not intended to provide the basis for any third-party evaluation of any securities or any offering of them and should not be considered as a recommendation that any recipient should subscribe for or purchase any securities.

The information contained herein is in summary form and does not purport to be complete. Certain information has been obtained from public sources. No representation or warranty, either express or implied, by the Company is made as to the accuracy, fairness, or completeness of the information presented herein and no reliance should be placed on the accuracy, fairness, or completeness of such information. The Company takes no responsibility or liability to update the contents of this presentation in the light of new information and/or future events. In addition, the Company may alter, modify or otherwise change in any manner the contents of this presentation, in its own discretion without the obligation to notify any person of such revision or changes.

This presentation contains “forward looking statements,” as that term is defined in Section 27 A of the U S Securities Act of 1933 as amended, and Section 21 E of the U S Securities Exchange Act of 1934 as amended. The words “ believe”; “ expect”; “ anticipate”; “ intend”; “ plan”; “ seeks”; “ estimates”; and “ and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. These factors include, without limitation, those discussed in our public reports filed with the Tokyo Stock Exchange and the Financial Services Agency of Japan. Although the Company believes that the expectations and assumptions reflected in the forward-looking statements are reasonably based on information currently available to the Company’s management, certain forward-looking statements are based upon assumptions of future events which may not prove to be accurate. The forward-looking statements in this document speak only as at the date of this presentation and the company does not assume any obligations to update or revise any of these forward statements, even if new information becomes available in the future.

This presentation does not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Recipients of this presentation are not to construe the contents of this summary as legal, tax or investment advice and recipients should consult their own advisors in this regard.

This presentation and its contents are proprietary confidential information and may not be reproduced, published or otherwise disseminated in whole or in part without the Company’s prior written consent. These materials are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

This presentation contains non-GAAP financial measures. The non-GAAP financial measures contained in this presentation are not measures of financial performance calculated in accordance with IFRS and should not be considered as replacements or alternatives profit, or operating profit, as an indicator of operating performance or as replacements or alternatives to cash flow provided by operating activities or as a measure of liquidity (in each case, as determined in accordance with IFRS). Non-GAAP financial measures should be viewed in addition to, and not as a substitute for, analysis of the Company’s results reported in accordance with IFRS.

(c) Nxera Pharma Co, Ltd, 2025. Nxera and the Nxera logos are trademarks of Nxera Pharma Co. Ltd.

Agenda

- 01 Opening Declaration
- 02 Report on number of voting rights
- 03 Audit Committee Audit Report
- 04 Business Report
- 05 Matters to be Resolved
- 06 Q&A
- 07 Vote
- 08 Closing Declaration

2

開会宣言

Opening Declaration

01

議決権個数のご報告

Report on the number of voting rights

02

監査委員会の監査報告

Audit Committee Audit Report

03

2025年12月期の連結業績・事業報告


FY2025 Consolidated Results Business Report

04




We've Been Here Before. We Are Fully Committed To Our 2030 Vision

SHARE PRICE (TSE: 4565): 2011-2016



SHARE PRICE (TSE 4565): 2023-2025



¥ 50B+


**FY2030
REVENUE**

30%+

**FY2030
OPERATING PROFIT MARGIN**

WE KNOW WHAT AN INVESTMENT CYCLE LOOKS LIKE. WE ARE BUILDING LONG-TERM VALUE

Our R&D Intensity of the Past 3 Years Was Intentional, It Was the Cost of Building Value




THE INVESTMENT PHASE IS CHANGING. THE RETURNS PHASE IS BEGINNING



An Investment in Nxera, Is an Investment in a Flywheel Of Innovation


STAR + SBDD

ORAVI



EACH BUSINESS LINE DESIGNED TO FUND, DE-RISK, AND STRENGTHEN THE OTHERS

Now, Let Us Show You What We Are Building



EACH BUSINESS LINE DESIGNED TO FUND, DE-RISK, AND STRENGTHEN THE OTHERS

In 3 Years, We Have Built a Japan Pharma Business That is Our Primary Revenue Engine

エンドセリン受容体拮抗薬 薬価基準収載
 **ピヴラッツ®** 点滴静注液 150mg

Standard of care – cerebral vasospasm prevention
 FY2025 net sales: ¥13.5B (+6.8% YoY)

MARKET LEADER

74%
 PIVLAZ® MARKET SHARE

不眠症治療薬 / オレキシン受容体拮抗薬 薬価基準未収載
 **クービビック®錠** 25mg / 50mg

Insomnia – launched Dec 2024 with Shionogi
 Phase 3 met all endpoints in South Korea; MAA submitted

HIGH GROWTH

+224%
 QUVUVIQ® SALES GROWTH

Vamorolone 

Duchenne Muscular Dystrophy – licensed from Santhera
 Approved in US, EU, UK, China

NEW ADDITION

70%
 SALES SYNERGY WITH PIVLAZ®

¥ –

FY2022 JAPAN REVENUE

¥17.8B

FY2025 REVENUE
 (+27.5% YoY)

PATIENT-CENTRIC FOUNDATION IN SPECIALTY, RARE AND PAEDIATRIC DISEASES. EXPECTED TO GROW RAPIDLY

Introducing Dr. Vasantha Gowda, Paediatric Neurologist With Patients On Vamorolone



- **Consultant paediatric neurologist with neuromuscular expertise** based at Evelina London Children's Hospital.
- Honorary appointment as a senior clinical lecturer at the faculty of life sciences and Medicine, King's College.



PROUD TO BRING VAMOROLONE TO JAPAN, SUPPORTING 2,000+ PATIENTS AND FAMILIES LIVING WITH DMD

"Giving Boys Living with DMD The Strength to Be a Kid!"

DUCHENNE MUSCULAR DYSTROPHY (DMD)

- **Rare and life-threatening neuromuscular disorder**
- Progressive muscle dysfunction leading to:
 - ambulation loss
 - respiratory failure
 - heart issues
 - premature death

VAMOROLONE

- ✓ Binds to the **same receptors as corticosteroids** but modifies the downstream activity of the receptors



APPROVED



- ✓ Confirmed **comparable long-term effectiveness** to traditional corticosteroids, for up to 8 years of treatment
- ✓ **Maintained growth** without compromising motor function
- ✓ Substantially **lower vertebral fracture risk** (80% reduction)
- ✓ Favorable **long-term ocular** and **metabolic profile**

PROUD TO BRING VAMOROLONE TO JAPAN, SUPPORTING 2,000+ PATIENTS AND FAMILIES LIVING WITH DMD

AI Drug Discovery Is an Inevitability. Our Proprietary Datasets Provide a 15 Year Head Start

PROPRIETARY DATA

“

When everyone trains on the same information, models inevitably converge. That's why AI is moving toward commoditization.

The real moat isn't the model itself. It's the proprietary data behind it.

Companies that can train on exclusive datasets gain an advantage competitors can't replicate.

”



Larry Ellison
Co-founder of Oracle

STAR + SBDD

493 GPCR structures

59 Receptors bound to **400+** unique SMEs


30,000 Mutation datapoints

100+ Projects



PROPRIETARY, EXCLUSIVE DATASETS, ORCHESTRATED IN OUR ORACLE DATA LAKE AND LARGE LANGUAGE MODELS

We Are Not Just Discovering Drugs, We Are Rebuilding How the World Discovers Them



**US\$5M
INVESTMENT
IN LONDON**




ANTHROPIC






AI+Q PLATFORM WILL TRANSFORM NXERA FROM A PHARMA COMPANY, INTO A TECHNOLOGY COMPANY

AI+Q Platform in Beta Development, With Activation Expected Late 2026


QUANTUM-LEVEL PRECISION

HIGH-SPEED SIMULATION



Residence Time (ns)

AI-DRIVEN MOLECULAR SIMULATION



MARKETED DRUG



PROOF OF CONCEPT

IN-HOUSE CHEMICAL SPACE 493 GPCR STRUCTURES

Focused Biotech Pipeline With The Potential To Transform Treatment Landscapes

Pre-2022

Rich History in Neurology

M1 ag.

M4 ag.

M1/M4 ag.

OX2 ag.



2026+

Building Across Metabolic & Rare Endocrine Disorders

GLP-1 ag.

Base-line obesity/chronic weight management therapy

GIP ag.

GIP ant.

Amylin ag.

GLP-1+ combination therapies for placebo-like tolerability, muscle preservation, enhanced weight loss

TSHR NAM

Thyroid eye disease

PTH ag.

Hypoparathyroidism

29 DEVELOPMENT CANDIDATES IN 10 YEARS – AN UNRIVALLED TRACK RECORD. THE NEXT WAVE OF CANDIDATES ARE COMING

Focused Biotech Pipeline, Addressing Real Global Unmet Need, And Currently Valued at Zero

	MARKET SIZE ¹	GLOBAL PATIENT POPULATION ²	STRONG STRATEGIC LOGIC
GLP-1 ag.	\$141B	1.0B	 Highly synergistic pipeline of metabolic combination therapies and rare disease anchors
GIP ag.	\$40B		 Metabolic therapies target 10% weight loss, placebo-like tolerability, muscle preservation
GIP ant.	\$10B		 Patients, and payors, seeking oral alternatives to expensive, chronic injectable therapies
Amylin ag.	\$20B		 Clinical endpoints are biomarker-driven, enabling fast, capital efficient de-risking
TSHR NAM	\$5.5B	50M	
PTH ag.	\$4.4B	275M	

CONVENIENT, ONCE-DAILY, DIFFERENTIATED ORAL SMALL MOLECULES AGAINST THE PEPTIDE-HORMONE GPCR AXIS

¹Estimated global market size in 2030 including mono and combination treatment; Source: Evaluate Pharma
²Estimated global patient population in 2030; Source: Evaluate Pharma

Three Clinical-Stage Programs, With a Plan to Transition to New Partners

EP4 ag. Inflammatory Bowel Disease

NXE'744 Phase 2-ready

Ph 1 completed successfully.
Ph 2 ready to initiate.

Showed early efficacy signals in an indomethacin challenge study.

In active discussions with 6 potential partners for a 2026 licence deal

GPR52 ag. Schizophrenia

NXE'149 Phase 2-ready

Ph 1 completed successfully.
Ph 2 ready to initiate.

Brain imaging suggest effect in brain regions similar to other antipsychotic drugs

In active discussions with 7 potential partners for a 2026 licence deal

EP4 ant. Cancer immunotherapy

NXE'732 Phase 2a ongoing

Interim Ph 2a data expected in H2 2026. ONO-4578 (EP4 ant) met primary endpoint in Ph 2 trial.

Showed early efficacy signals, including two partial responses.

Cancer Research UK managing ongoing Phase 2a clinical trial

NEW PARTNERSHIPS ARE EXPECTED IN 2026


The World's Leading Companies Turn to Nxera to Support Their Most Difficult GPCR Programs

	LEAD ASSET PHASE	PARTNER	TOTAL POTENTIAL DEAL VALUE ¹
Muscarinic agonists Neuropsychiatry	NBI-568 Phase 3		\$2.6B
Orexin 2 agonists Sleep disorders	ORX750 Phase 2		Milestones, royalties + equity stake
Multi-target Diabetes & Metabolic	Discovery		\$800M
Multi-target Neuroscience	Discovery		\$1.2B

NON-DILUTIVE SOURCE OF CAPITAL. GLOBAL REACH FROM A JAPANESE BASE

¹; Potential option fees, development, regulatory and commercial milestone payments agreed at the time of transaction. Nxera is also eligible to receive tiered royalties ranging from high single digit to mid-teen percentage on future net sales of any products developed under the partnership.

We Are Building Towards An Inflection Point



WE ARE ON WHAT INVESTORS CALL THE J-CURVE. THE RETURNS PHASE LIES AHEAD

Share price as at 4-March 2026

We Are Entering An Era of Efficiency, As Technology Drives New Ways of Working

FY2025 ACTUAL

¥29.6B revenue **¥20.4B** cash



FY2026 GUIDANCE → BREAKEVEN IN SIGHT

¥33.8B revenue **¥7.8B** core operating profit

Generation

- FY2026 sales growth target (PIVLAZ: +5%, QUVIVIQ + 30%)
- Partner milestones from NBIX, CNTA, LLY, ABBV
- GPR52 / EP4 out-licensing

Discipline

- ~30% global headcount reduction achieved since FY2023
- Multiple pipeline programs killed
- ~10% further cost reduction expected in FY2026

2030 Vision

- High growth, highly profitable Japanese biopharma
- ≥JPY 50B revenue target
- ≥30% operating margin

DISCIPLINED WITH CAPITAL ALLOCATION. EVERY INVESTMENT IN R&D HAS STRICT GO/NO-GO CRITERIA



Every Leader is a Shareholder in Nxera. Our Interests Are Aligned With Yours



CHRIS CARGILL
Chief Executive

Group Strategy
and Execution



HIRO NOMURA
Chief Financial

Group Capital
Structure,
IR and BD



TOSHI MAEDA
Chief Operating

*President Nxera
Pharma Japan*
JAPAC Clinical and
Commercial



PATRIK FOERCH
Chief Scientific

*President Nxera
Pharma UK*
UK Research and
Development



KIERAN JOHNSON
Chief Accounting

Group Treasury
and Financial
Reporting



CANDELLE CHONG
Chief of Staff

Group Corporate
Functions



MARIKO NAKAFUJI
Chief Legal

Group Legal &
Compliance

THE LEADERSHIP TEAM THAT BUILT NXERA, IS THE LEADERSHIP TEAM THAT WILL DELIVER THE NEXT ERA

Credibility Will Be Built Upon Delivery, Milestone by Milestone

2026 CATALYSTS

2027 CATALYSTS

AI+Q Application of structure ensembles in design

AI+Q Quantum inspired equivariant couplings for co-folding

AI+Q First optimized lead programs generated from AI+Q platform

Amylin ag Dev. candidate

TSH NAM Dev. candidate

GIP ant IND-enabling studies


Metabolic/Endocrine

Next wave of programs generated from Platform

AI+Q
Launch of AI+Q
Drug Discovery Platform

EP4 ant Interim Ph 2a data

GIP ant Development candidate



QUVIVIQ Korea MAA submission

QUVIVIQ Taiwan approval

Vamorolone In-licensing

NBIX M1/M4 Ph 2 start

NBIX M1 Ph 1 data

NBIX M1/M4 Ph 1 data

CNTA ORX750 Ph 2a data

CNTA ORX142 Ph 2 start

CNTA ORX489 Ph 1 start

PFE MC4 Ph 1 data

SNZA New PAR2 assetco

EP4 ag Out-licensing

GPR52 ag Out-licensing

QUVIVIQ

Korea approval/launch

Vamorolone


JNDA submission

NBIX M4 Ph 3 data

NBIX M4 NDA filing

SNZA PAR2 Ph1a data

Execution is Our Innovation. Join Us On the Journey.



THE NEXT CHAPTER OF NXERA IS NOT WRITTEN. THE FOUNDATION IS LAID. THE STRATEGY CLEAR. THE TEAM IS READY

決議事項

Matters to be Resolved

05

Proposal

Election of Seven (7) Directors

1	Christopher Cargill	Chairman of the Board, Representative Executive Officer, President & CEO Chair of the Nomination Committee, Member of the Compensation Committee	RE-APPOINTED		
2	David Roblin	External Director, Chair of the Compensation Committee, Member of the Nomination Committee	RE-APPOINTED	EXTERNAL	INDEPENDENT
3	Rolf Soderstrom	External Director, Chair of the Audit Committee, Member of the Compensation Committee	RE-APPOINTED	EXTERNAL	INDEPENDENT
4	Eiko Tomita	External Director Member of the Audit Committee	RE-APPOINTED	EXTERNAL	INDEPENDENT
5	Naoko Shimura	External Director Member of the Audit Committee	RE-APPOINTED	EXTERNAL	
6	Nicola Rabson	External Director Member of the Audit Committee	RE-APPOINTED	EXTERNAL	INDEPENDENT
7	Takeo Morooka	-	NEWLY APPOINTED	EXTERNAL	INDEPENDENT

Note: Current positions and responsibilities at the Company are presented

質疑応答

Q&A



採決

Vote

07

閉会宣言

Closing Declaration

08



Locations



Midtown East,
9-7-2 Akasaka
Minato-ku
Tokyo 107-0052

Japan



F17, 410 Teheran-
Ro
GangHam-Gu
Seoul 06192

South Korea



Steinmetz Building
Granta Park,
Cambridge
CB21 6DG

United Kingdom



Spaces Grosspeter
Tower,
Grosspeteranlage
29,
4052 Basel

Switzerland